A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
A phase 2 trial of Abexinostat in non-Hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.
Overview
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03934567 by Xynomic Pharmaceuticals, Inc., with 87 participants enrolled, started 2020-04-22 and due to reach its primary completion in 2025-01-29. Interventions recorded: Abexinostat.
Similar pages
not linked directly; found by shared links- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.